L
Leon W. Hoyer
Researcher at American Red Cross
Publications - 51
Citations - 4301
Leon W. Hoyer is an academic researcher from American Red Cross. The author has contributed to research in topics: Antibody & Antigen. The author has an hindex of 27, co-authored 51 publications receiving 4261 citations. Previous affiliations of Leon W. Hoyer include George Washington University.
Papers
More filters
Journal ArticleDOI
Synthesis of Antihemophilic Factor Antigen by Cultured Human Endothelial Cells
TL;DR: It is established that exogenous AHF procoagulant activity is not inactivated by the tissue culture system.
Journal ArticleDOI
Synthesis of von Willebrand Factor by Cultured Human Endothelial Cells
TL;DR: The Von Willebrand factor activity from cultured endothelial cells has physicochemical and immunologic properties like those of the von Wille Brand factor activity and the Factor VIII antigen present in human plasma and theFactor VIII antigen synthesized by human endothelium cells in vitro.
Journal ArticleDOI
Antihemophilic factor antigen. Localization in endothelial cells by immunofluorescent microscopy.
TL;DR: The demonstration of fluorescence within the cytoplasm of endothelial cells suggests that these cells synthesize proteins that have AHF antigens, which is in line with previous reports on antihemophilic factor.
Journal ArticleDOI
Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
Dorothea Scandella,Gary E. Gilbert,Midori Shima,Hiroaki Nakai,Christine Eagleson,Matthew Felch,Richard Prescott,K.J. Rajalakshmi,Leon W. Hoyer,Evgueni L. Saenko +9 more
TL;DR: It is proposed that fVIII inhibition by anti-C2 antibodies is related to the overlap of their epitopes with the PS-binding site, and that some antibodies within the polyclonal anti-light chain population require only amino acids within C2 for binding.
Journal ArticleDOI
Prevention and treatment of factor VIII inhibitors in murine hemophilia A.
TL;DR: It is suggested that strategies targeting the B7-CD28 pathway are potential therapies to prevent and treat inhibitory antifactor VIII antibodies.